Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment
Mei Huang, … , Marjan Azin, Shadmehr Demehri
Mei Huang, … , Marjan Azin, Shadmehr Demehri
Published October 16, 2023
Citation Information: J Clin Invest. 2023;133(20):e166494. https://doi.org/10.1172/JCI166494.
View: Text | PDF
Research Article Oncology

Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment

  • Text
  • PDF
Abstract

Carcinogen exposure is strongly associated with enhanced cancer immunogenicity. Increased tumor mutational burden and resulting neoantigen generation have been proposed to link carcinogen exposure and cancer immunogenicity. However, the neoantigen-independent immunological impact of carcinogen exposure on cancer is unknown. Here, we demonstrate that chemical carcinogen-exposed cancer cells fail to establish an immunosuppressive tumor microenvironment (TME), resulting in their T cell–mediated rejection in vivo. A chemical carcinogen-treated breast cancer cell clone that lacked any additional coding region mutations (i.e., neoantigen) was rejected in mice in a T cell–dependent manner. Strikingly, the coinjection of carcinogen- and control-treated cancer cells prevented this rejection, suggesting that the loss of immunosuppressive TME was the dominant cause of rejection. Reduced M-CSF expression by carcinogen-treated cancer cells significantly suppressed tumor-associated macrophages (TAMs) and resulted in the loss of an immunosuppressive TME. Single-cell analysis of human lung cancers revealed a significant reduction in the immunosuppressive TAMs in former smokers compared with individuals who had never smoked. These findings demonstrate that carcinogen exposure impairs the development of an immunosuppressive TME and indicate a novel link between carcinogens and cancer immunogenicity.

Authors

Mei Huang, Yun Xia, Kaiwen Li, Feng Shao, Zhaoyi Feng, Tiancheng Li, Marjan Azin, Shadmehr Demehri

×

Figure 3

Carcinogen-exposed cancer cells do not form an immunosuppressive TME.

Options: View larger image (or click on image) Download as PowerPoint
Carcinogen-exposed cancer cells do not form an immunosuppressive TME.
(A...
(A) Schematic illustration of DMBA3-4 and DMSO3-1 cell coinjection into WT mice. (B) DMBA3-4 and DMSO3-1 tumor growth simultaneously in WT mice (n = 5 per group). 100,000 DMBA3-4 cells (left side) and 100,000 DMSO3-1 cells (right side) were injected into each mouse at the same time. (C) DMBA3-4 and DMSO3-1 tumor growth in WT mice injected with 500,000 DMBA3-4 cells (left side) and 50,000 DMSO3-1 cells (right side) (n = 5 per group). Red arrows point to a DMBA3-4 tumor that grew out and its contralateral DMSO3-1 tumor in the same WT mouse. (D) Macroscopic and H&E-stained histological images of DMBA3-4 (left) and DMSO3-1 (right) tumors in the same WT mouse. Scale bars: 1 cm, mouse; 100 μm, histology. (E) DMBA3-4 plus DMSO3-1 mixed tumor compared with DMSO3-1 alone tumor growth in WT mice (n = 8 for 450,000 DMBA3-4 plus 50,000 DMSO3-1; n = 10 for 50,000 DMBA3-4 plus 50,000 DMSO3-1; and n = 8 for 50,000 DMSO3-1 group). (F) Representative macroscopic and H&E-stained histological images of DMBA3-4 plus DMSO3-1 mixed and DMSO3-1 alone tumors in WT mice. Scale bars: 1 cm, mouse; 100 μm, histology. 2-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts